Abstract
Chronic heart failure is a major public health problem causing considerable morbidity and mortality. Recent studies have shown that an elevated plasma level of homocysteine is a strong independent risk factor for heart failure, in addition to atherosclerotic disease. Preclinical studies have demonstrated that induced hyperhomocysteinemia acts via multiple pathogenic mechanisms, including inflammation and oxidative stress, to promote adverse cardiac remodeling and failure. However, clinical studies have not conclusively shown a causative relation between hyperhomocysteinemia and cardiovascular disease. This article will review current data concerning homocysteine and its pathogenic relationship to heart failure.
Keywords: Homocysteine, Heart Failure, Remodeling, Cardiovascular Disease, morbidity, mortality, atherosclerotic disease, oxidative stress, atherothrombotic, spironolactone, hypertension, diabetes mellitus, obesity, B-type, natriuretic peptide, hyperuricaemia, echocardiographic signs, diastolic diameter, methionine, cystathionine, methyltetrahydrofolate, adenosylmethionine, neurohormonal model, angiotensin-converting enzyme, fibrosis, tumor necrosis, myocardium, Interleukins-1, matrix metalloproteinases, Cathepsin G, anti-oxidant vitamin, Coronary artery disease
Cardiovascular & Hematological Disorders-Drug Targets
Title: Homocysteine, Cardiovascular Inflammation, and Myocardial Remodeling
Volume: 10 Issue: 4
Author(s): Jennifer M. Finch and Jacob Joseph
Affiliation:
Keywords: Homocysteine, Heart Failure, Remodeling, Cardiovascular Disease, morbidity, mortality, atherosclerotic disease, oxidative stress, atherothrombotic, spironolactone, hypertension, diabetes mellitus, obesity, B-type, natriuretic peptide, hyperuricaemia, echocardiographic signs, diastolic diameter, methionine, cystathionine, methyltetrahydrofolate, adenosylmethionine, neurohormonal model, angiotensin-converting enzyme, fibrosis, tumor necrosis, myocardium, Interleukins-1, matrix metalloproteinases, Cathepsin G, anti-oxidant vitamin, Coronary artery disease
Abstract: Chronic heart failure is a major public health problem causing considerable morbidity and mortality. Recent studies have shown that an elevated plasma level of homocysteine is a strong independent risk factor for heart failure, in addition to atherosclerotic disease. Preclinical studies have demonstrated that induced hyperhomocysteinemia acts via multiple pathogenic mechanisms, including inflammation and oxidative stress, to promote adverse cardiac remodeling and failure. However, clinical studies have not conclusively shown a causative relation between hyperhomocysteinemia and cardiovascular disease. This article will review current data concerning homocysteine and its pathogenic relationship to heart failure.
Export Options
About this article
Cite this article as:
M. Finch Jennifer and Joseph Jacob, Homocysteine, Cardiovascular Inflammation, and Myocardial Remodeling, Cardiovascular & Hematological Disorders-Drug Targets 2010; 10 (4) . https://dx.doi.org/10.2174/187152910793743887
DOI https://dx.doi.org/10.2174/187152910793743887 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Salutary Properties of YC-1 in the Cardiovascular and Hematological Systems
Current Medicinal Chemistry - Cardiovascular & Hematological Agents MicroRNAs: Modulators of Cell Identity, and their Applications in Tissue Engineering
MicroRNA Role of Bradykinin in the Regulation of Endothelial Nitric Oxide Synthase Expression by Cardiovascular Drugs
Current Pharmaceutical Design Editorial: Time for Earlier and More Intensive Preventive Therapy
Current Vascular Pharmacology Dyspnea in Cancer Patients: A Well-Known and Neglected Symptom
Reviews on Recent Clinical Trials Evaluation Approach can Significantly Influence Oral Glucose-Lowering Drugs Total Mortality Risks in Retrospective Cohorts of Type 2 Diabetes Mellitus Patients
Current Diabetes Reviews Role of Mitochondria on Muscle Cell Death and Meat Tenderization
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Fabry Cardiomyopathy - Diagnostic Approach and Current Treatment
Current Pharmaceutical Design Role of Opioid Antagonists in the Treatment of Women with Glucoregulation Abnormalities
Current Pharmaceutical Design Improvement in Hypertension Management with Pharmacological and Non- Pharmacological Approaches: Current Perspectives
Current Pharmaceutical Design Stroke as a Consequence of Sleep Apnea: Epidemiology, Pathophysiology and Treatment Strategies
Current Respiratory Medicine Reviews Emerging Anti-inflammatory Therapies for Atherosclerosis
Current Pharmaceutical Design Hypoxia-Inducible Factor-1 in Arterial Disease: A Putative Therapeutic Target
Current Vascular Pharmacology SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature
Current Pharmaceutical Design Diabetic Cardiovascular Disease – AMP-Activated Protein Kinase (AMPK) as a Therapeutic Target
Cardiovascular & Hematological Agents in Medicinal Chemistry Ascorbic Acid: Its Role in Immune System and Chronic Inflammation Diseases
Mini-Reviews in Medicinal Chemistry Dimer and Tetramer of Gallic Acid: Facile Synthesis, Antioxidant and Antiproliferative Activities
Letters in Drug Design & Discovery Editorial: Inflammation and Heart Diseases
Current Pharmaceutical Design Hydrogen Sulfide Regulates Vascular Inflammation and its Related Signaling Pathways
Current Signal Transduction Therapy Targeting Cytokines, Chemokines and Adhesion Molecules in Rheumatoid Arthritis
Current Rheumatology Reviews